Global Sinusitis Drugs Market

Sinusitis Drugs Comprehensive Study by Type (Analgesics, Antibiotics, Antihistamines, Corticosteroids, Decongestants, Sulphonamides), Application (Acute Sinusitis, Chronic Sinusitis), Treatment (Antibiotics, NSAIDS, Decongestant and Mucolytic, Nasal Irrigation), End User (Adults, Teenagers, Children) Players and Region - Global Market Outlook to 2026

Sinusitis Drugs Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
What is Sinusitis Drugs Market Scope?
Sinusitis drugs or medicines are used for sinus infection or rhinosinusitis which is caused due to the inflammation of the sinuses creating other issues and symptoms like the plugged nose, pain in the face, thick nasal mucus headache,m fever, sore throat, and others. Drugs range such as analgesics, antibiotics, antihistamines, corticosteroids, decongestants, sulphonamides is consumed for sinus. These sinusitis drugs are prescribed according to the sinus infection which ranges from acute or chronic sinusitis.

Influencing Trend:
Continuous Research and Development in the Sinusitis Drugs and Increasing Consumption of Analgesics and Antibiotics as Sinusitis Drugs

Market Growth Drivers:
Rising Prevalence of Sinus Infection Among Different Range of People and Need for Treating the Sinus Infection and Other Health Problems Associated with it

Challenges:
Stiff Competition due to New Entrants in the Sinusitis Drugs Market

Restraints:
Side Effects Associated with the Consumption of Sinusitis Drugs

Opportunities:
Surging Awareness about the Regular Checkups will Boost the Sinusitis Drugs Market

The Sinusitis Drugs market study is being classified by Type (Analgesics, Antibiotics, Antihistamines, Corticosteroids, Decongestants and Sulphonamides), by Application and major geographies with country level break-up.

Sanofi S.A. (France), Pfizer Inc. (United States), Novartis International AG (Switzerland), Johnson & Johnson (United States), Merck & Co., Inc. (United States), AstraZeneca plc (United Kingdom), Amgen Inc. (United States) and Teva Pharmaceutical Industries Ltd. (Israel) are some of the key players profiled in the study.

Segmentation Analysis
Analyst at AMA have segmented the market study of Global Sinusitis Drugs market by Type, Application and Region.

On the basis of geography, the market of Sinusitis Drugs has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).

On 6th August 2020, Novartis announced that the European Commission (EC) has approved Xolair (omalizumab) as add-on therapy with intranasal corticosteroids (INC) for the treatment of adults (18 years and above) with severe chronic rhinosinusitis with nasal polyps (CRSwNP) for whom therapy with INC does not provide adequate disease control1. Phase III studies have shown that Xolair reduces nasal polyp size (defined by Nasal Polyp Score; NPS) and improves symptoms and quality of life in patients with CRSwNP5. Xolair is the first treatment for CRSwNP specifically targeting and blocking immunoglobulin E (IgE), a key driver in the inflammatory pathway of this disease.
"Dupixent is the first FDA approved medicine for adults with chronic rhinosinusitis with nasal polyposis, and the only approved therapy has shown to shrink nasal polyp size and also improve the signs and symptoms of the associated chronic rhinosinusitis."

Key Target Audience
Sinusitis Drugs Manufacturers, Sinusitis Drugs International Traders, Sinusitis Drugs Distributors and Suppliers, Research and Development Institutes, Potential Investors, Regulatory Bodies and Others

Sinusitis Drugs Market Study: Important Years
AttributesDetails
Study Period2017-2027
Base Year2021
Forecast Period2022-2027
Historical Period2017-2021
UnitValue (USD Million)
Customization ScopeAvail customization with purchase of this report. Add or modify country, region & or narrow down segments in the final scope subject to feasibility


Major Highlights of Market Study

Demand Determinants: Identifying top-notch application and business segments that seek high growth potentials in Sinusitis Drugs Market.

Key Strategic Developments: To target untapped regions more aggressively by focusing on product/service developments, innovation and R & D, new launches, Merger & acquisitions, JVs & partnerships.

Forces & Market Dynamics: Growth drivers, restraints & opportunities available in Sinusitis Drugs industry is examined with reference relevant market sectors and sub-sectors.

Customization available in this Study:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.

To compete effectively, companies also require quantitative estimates of the future growth and qualitative nature of the market. AMA Research features not just specific market sizing estimates, but also includes significant value-added commentary on Technological Trends and Innovations, Regulatory Policies, Market Maturity Indicators, Market Share Movements, New Entrants into the Market & Entry/Exit Barriers, Consumer Demographics, Supporting Company Financial and Cash Flow Planning, Open Up New Markets, To Seize Powerful Market Opportunities, Key Decision in Planning and to Further Expand Market Share, Identify Key Business Segments, Market Proposition & Gap Analysis.

Report Objectives / Segmentation Covered

By Type
  • Analgesics
  • Antibiotics
  • Antihistamines
  • Corticosteroids
  • Decongestants
  • Sulphonamides
By Application
  • Acute Sinusitis
  • Chronic Sinusitis
By Treatment
  • Antibiotics
  • NSAIDS
  • Decongestant and Mucolytic
  • Nasal Irrigation

By End User
  • Adults
  • Teenagers
  • Children

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising Prevalence of Sinus Infection Among Different Range of People
      • 3.2.2. Need for Treating the Sinus Infection and Other Health Problems Associated with it
    • 3.3. Market Challenges
      • 3.3.1. Stiff Competition due to New Entrants in the Sinusitis Drugs Market
    • 3.4. Market Trends
      • 3.4.1. Continuous Research and Development in the Sinusitis Drugs
      • 3.4.2. Increasing Consumption of Analgesics and Antibiotics as Sinusitis Drugs
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Sinusitis Drugs, by Type, Application, Treatment, End User and Region (value) (2016-2021)
    • 5.1. Introduction
    • 5.2. Global Sinusitis Drugs (Value)
      • 5.2.1. Global Sinusitis Drugs by: Type (Value)
        • 5.2.1.1. Analgesics
        • 5.2.1.2. Antibiotics
        • 5.2.1.3. Antihistamines
        • 5.2.1.4. Corticosteroids
        • 5.2.1.5. Decongestants
        • 5.2.1.6. Sulphonamides
      • 5.2.2. Global Sinusitis Drugs by: Application (Value)
        • 5.2.2.1. Acute Sinusitis
        • 5.2.2.2. Chronic Sinusitis
      • 5.2.3. Global Sinusitis Drugs by: Treatment (Value)
        • 5.2.3.1. Antibiotics
        • 5.2.3.2. NSAIDS
        • 5.2.3.3. Decongestant and Mucolytic
        • 5.2.3.4. Nasal Irrigation
      • 5.2.4. Global Sinusitis Drugs by: End User (Value)
        • 5.2.4.1. Adults
        • 5.2.4.2. Teenagers
        • 5.2.4.3. Children
      • 5.2.5. Global Sinusitis Drugs Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Sinusitis Drugs: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2021)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Sanofi S.A. (France)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Pfizer Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Novartis International AG (Switzerland)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Johnson & Johnson (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Merck & Co., Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. AstraZeneca plc (United Kingdom)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Amgen Inc. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Teva Pharmaceutical Industries Ltd. (Israel)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
  • 7. Global Sinusitis Drugs Sale, by Type, Application, Treatment, End User and Region (value) (2022-2027)
    • 7.1. Introduction
    • 7.2. Global Sinusitis Drugs (Value)
      • 7.2.1. Global Sinusitis Drugs by: Type (Value)
        • 7.2.1.1. Analgesics
        • 7.2.1.2. Antibiotics
        • 7.2.1.3. Antihistamines
        • 7.2.1.4. Corticosteroids
        • 7.2.1.5. Decongestants
        • 7.2.1.6. Sulphonamides
      • 7.2.2. Global Sinusitis Drugs by: Application (Value)
        • 7.2.2.1. Acute Sinusitis
        • 7.2.2.2. Chronic Sinusitis
      • 7.2.3. Global Sinusitis Drugs by: Treatment (Value)
        • 7.2.3.1. Antibiotics
        • 7.2.3.2. NSAIDS
        • 7.2.3.3. Decongestant and Mucolytic
        • 7.2.3.4. Nasal Irrigation
      • 7.2.4. Global Sinusitis Drugs by: End User (Value)
        • 7.2.4.1. Adults
        • 7.2.4.2. Teenagers
        • 7.2.4.3. Children
      • 7.2.5. Global Sinusitis Drugs Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Sinusitis Drugs: by Type(USD Million)
  • Table 2. Sinusitis Drugs Analgesics , by Region USD Million (2016-2021)
  • Table 3. Sinusitis Drugs Antibiotics , by Region USD Million (2016-2021)
  • Table 4. Sinusitis Drugs Antihistamines , by Region USD Million (2016-2021)
  • Table 5. Sinusitis Drugs Corticosteroids , by Region USD Million (2016-2021)
  • Table 6. Sinusitis Drugs Decongestants , by Region USD Million (2016-2021)
  • Table 7. Sinusitis Drugs Sulphonamides , by Region USD Million (2016-2021)
  • Table 8. Sinusitis Drugs: by Application(USD Million)
  • Table 9. Sinusitis Drugs Acute Sinusitis , by Region USD Million (2016-2021)
  • Table 10. Sinusitis Drugs Chronic Sinusitis , by Region USD Million (2016-2021)
  • Table 11. Sinusitis Drugs: by Treatment(USD Million)
  • Table 12. Sinusitis Drugs Antibiotics , by Region USD Million (2016-2021)
  • Table 13. Sinusitis Drugs NSAIDS , by Region USD Million (2016-2021)
  • Table 14. Sinusitis Drugs Decongestant and Mucolytic , by Region USD Million (2016-2021)
  • Table 15. Sinusitis Drugs Nasal Irrigation , by Region USD Million (2016-2021)
  • Table 16. Sinusitis Drugs: by End User(USD Million)
  • Table 17. Sinusitis Drugs Adults , by Region USD Million (2016-2021)
  • Table 18. Sinusitis Drugs Teenagers , by Region USD Million (2016-2021)
  • Table 19. Sinusitis Drugs Children , by Region USD Million (2016-2021)
  • Table 20. South America Sinusitis Drugs, by Country USD Million (2016-2021)
  • Table 21. South America Sinusitis Drugs, by Type USD Million (2016-2021)
  • Table 22. South America Sinusitis Drugs, by Application USD Million (2016-2021)
  • Table 23. South America Sinusitis Drugs, by Treatment USD Million (2016-2021)
  • Table 24. South America Sinusitis Drugs, by End User USD Million (2016-2021)
  • Table 25. Brazil Sinusitis Drugs, by Type USD Million (2016-2021)
  • Table 26. Brazil Sinusitis Drugs, by Application USD Million (2016-2021)
  • Table 27. Brazil Sinusitis Drugs, by Treatment USD Million (2016-2021)
  • Table 28. Brazil Sinusitis Drugs, by End User USD Million (2016-2021)
  • Table 29. Argentina Sinusitis Drugs, by Type USD Million (2016-2021)
  • Table 30. Argentina Sinusitis Drugs, by Application USD Million (2016-2021)
  • Table 31. Argentina Sinusitis Drugs, by Treatment USD Million (2016-2021)
  • Table 32. Argentina Sinusitis Drugs, by End User USD Million (2016-2021)
  • Table 33. Rest of South America Sinusitis Drugs, by Type USD Million (2016-2021)
  • Table 34. Rest of South America Sinusitis Drugs, by Application USD Million (2016-2021)
  • Table 35. Rest of South America Sinusitis Drugs, by Treatment USD Million (2016-2021)
  • Table 36. Rest of South America Sinusitis Drugs, by End User USD Million (2016-2021)
  • Table 37. Asia Pacific Sinusitis Drugs, by Country USD Million (2016-2021)
  • Table 38. Asia Pacific Sinusitis Drugs, by Type USD Million (2016-2021)
  • Table 39. Asia Pacific Sinusitis Drugs, by Application USD Million (2016-2021)
  • Table 40. Asia Pacific Sinusitis Drugs, by Treatment USD Million (2016-2021)
  • Table 41. Asia Pacific Sinusitis Drugs, by End User USD Million (2016-2021)
  • Table 42. China Sinusitis Drugs, by Type USD Million (2016-2021)
  • Table 43. China Sinusitis Drugs, by Application USD Million (2016-2021)
  • Table 44. China Sinusitis Drugs, by Treatment USD Million (2016-2021)
  • Table 45. China Sinusitis Drugs, by End User USD Million (2016-2021)
  • Table 46. Japan Sinusitis Drugs, by Type USD Million (2016-2021)
  • Table 47. Japan Sinusitis Drugs, by Application USD Million (2016-2021)
  • Table 48. Japan Sinusitis Drugs, by Treatment USD Million (2016-2021)
  • Table 49. Japan Sinusitis Drugs, by End User USD Million (2016-2021)
  • Table 50. India Sinusitis Drugs, by Type USD Million (2016-2021)
  • Table 51. India Sinusitis Drugs, by Application USD Million (2016-2021)
  • Table 52. India Sinusitis Drugs, by Treatment USD Million (2016-2021)
  • Table 53. India Sinusitis Drugs, by End User USD Million (2016-2021)
  • Table 54. South Korea Sinusitis Drugs, by Type USD Million (2016-2021)
  • Table 55. South Korea Sinusitis Drugs, by Application USD Million (2016-2021)
  • Table 56. South Korea Sinusitis Drugs, by Treatment USD Million (2016-2021)
  • Table 57. South Korea Sinusitis Drugs, by End User USD Million (2016-2021)
  • Table 58. Taiwan Sinusitis Drugs, by Type USD Million (2016-2021)
  • Table 59. Taiwan Sinusitis Drugs, by Application USD Million (2016-2021)
  • Table 60. Taiwan Sinusitis Drugs, by Treatment USD Million (2016-2021)
  • Table 61. Taiwan Sinusitis Drugs, by End User USD Million (2016-2021)
  • Table 62. Australia Sinusitis Drugs, by Type USD Million (2016-2021)
  • Table 63. Australia Sinusitis Drugs, by Application USD Million (2016-2021)
  • Table 64. Australia Sinusitis Drugs, by Treatment USD Million (2016-2021)
  • Table 65. Australia Sinusitis Drugs, by End User USD Million (2016-2021)
  • Table 66. Rest of Asia-Pacific Sinusitis Drugs, by Type USD Million (2016-2021)
  • Table 67. Rest of Asia-Pacific Sinusitis Drugs, by Application USD Million (2016-2021)
  • Table 68. Rest of Asia-Pacific Sinusitis Drugs, by Treatment USD Million (2016-2021)
  • Table 69. Rest of Asia-Pacific Sinusitis Drugs, by End User USD Million (2016-2021)
  • Table 70. Europe Sinusitis Drugs, by Country USD Million (2016-2021)
  • Table 71. Europe Sinusitis Drugs, by Type USD Million (2016-2021)
  • Table 72. Europe Sinusitis Drugs, by Application USD Million (2016-2021)
  • Table 73. Europe Sinusitis Drugs, by Treatment USD Million (2016-2021)
  • Table 74. Europe Sinusitis Drugs, by End User USD Million (2016-2021)
  • Table 75. Germany Sinusitis Drugs, by Type USD Million (2016-2021)
  • Table 76. Germany Sinusitis Drugs, by Application USD Million (2016-2021)
  • Table 77. Germany Sinusitis Drugs, by Treatment USD Million (2016-2021)
  • Table 78. Germany Sinusitis Drugs, by End User USD Million (2016-2021)
  • Table 79. France Sinusitis Drugs, by Type USD Million (2016-2021)
  • Table 80. France Sinusitis Drugs, by Application USD Million (2016-2021)
  • Table 81. France Sinusitis Drugs, by Treatment USD Million (2016-2021)
  • Table 82. France Sinusitis Drugs, by End User USD Million (2016-2021)
  • Table 83. Italy Sinusitis Drugs, by Type USD Million (2016-2021)
  • Table 84. Italy Sinusitis Drugs, by Application USD Million (2016-2021)
  • Table 85. Italy Sinusitis Drugs, by Treatment USD Million (2016-2021)
  • Table 86. Italy Sinusitis Drugs, by End User USD Million (2016-2021)
  • Table 87. United Kingdom Sinusitis Drugs, by Type USD Million (2016-2021)
  • Table 88. United Kingdom Sinusitis Drugs, by Application USD Million (2016-2021)
  • Table 89. United Kingdom Sinusitis Drugs, by Treatment USD Million (2016-2021)
  • Table 90. United Kingdom Sinusitis Drugs, by End User USD Million (2016-2021)
  • Table 91. Netherlands Sinusitis Drugs, by Type USD Million (2016-2021)
  • Table 92. Netherlands Sinusitis Drugs, by Application USD Million (2016-2021)
  • Table 93. Netherlands Sinusitis Drugs, by Treatment USD Million (2016-2021)
  • Table 94. Netherlands Sinusitis Drugs, by End User USD Million (2016-2021)
  • Table 95. Rest of Europe Sinusitis Drugs, by Type USD Million (2016-2021)
  • Table 96. Rest of Europe Sinusitis Drugs, by Application USD Million (2016-2021)
  • Table 97. Rest of Europe Sinusitis Drugs, by Treatment USD Million (2016-2021)
  • Table 98. Rest of Europe Sinusitis Drugs, by End User USD Million (2016-2021)
  • Table 99. MEA Sinusitis Drugs, by Country USD Million (2016-2021)
  • Table 100. MEA Sinusitis Drugs, by Type USD Million (2016-2021)
  • Table 101. MEA Sinusitis Drugs, by Application USD Million (2016-2021)
  • Table 102. MEA Sinusitis Drugs, by Treatment USD Million (2016-2021)
  • Table 103. MEA Sinusitis Drugs, by End User USD Million (2016-2021)
  • Table 104. Middle East Sinusitis Drugs, by Type USD Million (2016-2021)
  • Table 105. Middle East Sinusitis Drugs, by Application USD Million (2016-2021)
  • Table 106. Middle East Sinusitis Drugs, by Treatment USD Million (2016-2021)
  • Table 107. Middle East Sinusitis Drugs, by End User USD Million (2016-2021)
  • Table 108. Africa Sinusitis Drugs, by Type USD Million (2016-2021)
  • Table 109. Africa Sinusitis Drugs, by Application USD Million (2016-2021)
  • Table 110. Africa Sinusitis Drugs, by Treatment USD Million (2016-2021)
  • Table 111. Africa Sinusitis Drugs, by End User USD Million (2016-2021)
  • Table 112. North America Sinusitis Drugs, by Country USD Million (2016-2021)
  • Table 113. North America Sinusitis Drugs, by Type USD Million (2016-2021)
  • Table 114. North America Sinusitis Drugs, by Application USD Million (2016-2021)
  • Table 115. North America Sinusitis Drugs, by Treatment USD Million (2016-2021)
  • Table 116. North America Sinusitis Drugs, by End User USD Million (2016-2021)
  • Table 117. United States Sinusitis Drugs, by Type USD Million (2016-2021)
  • Table 118. United States Sinusitis Drugs, by Application USD Million (2016-2021)
  • Table 119. United States Sinusitis Drugs, by Treatment USD Million (2016-2021)
  • Table 120. United States Sinusitis Drugs, by End User USD Million (2016-2021)
  • Table 121. Canada Sinusitis Drugs, by Type USD Million (2016-2021)
  • Table 122. Canada Sinusitis Drugs, by Application USD Million (2016-2021)
  • Table 123. Canada Sinusitis Drugs, by Treatment USD Million (2016-2021)
  • Table 124. Canada Sinusitis Drugs, by End User USD Million (2016-2021)
  • Table 125. Mexico Sinusitis Drugs, by Type USD Million (2016-2021)
  • Table 126. Mexico Sinusitis Drugs, by Application USD Million (2016-2021)
  • Table 127. Mexico Sinusitis Drugs, by Treatment USD Million (2016-2021)
  • Table 128. Mexico Sinusitis Drugs, by End User USD Million (2016-2021)
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Sinusitis Drugs: by Type(USD Million)
  • Table 138. Sinusitis Drugs Analgesics , by Region USD Million (2022-2027)
  • Table 139. Sinusitis Drugs Antibiotics , by Region USD Million (2022-2027)
  • Table 140. Sinusitis Drugs Antihistamines , by Region USD Million (2022-2027)
  • Table 141. Sinusitis Drugs Corticosteroids , by Region USD Million (2022-2027)
  • Table 142. Sinusitis Drugs Decongestants , by Region USD Million (2022-2027)
  • Table 143. Sinusitis Drugs Sulphonamides , by Region USD Million (2022-2027)
  • Table 144. Sinusitis Drugs: by Application(USD Million)
  • Table 145. Sinusitis Drugs Acute Sinusitis , by Region USD Million (2022-2027)
  • Table 146. Sinusitis Drugs Chronic Sinusitis , by Region USD Million (2022-2027)
  • Table 147. Sinusitis Drugs: by Treatment(USD Million)
  • Table 148. Sinusitis Drugs Antibiotics , by Region USD Million (2022-2027)
  • Table 149. Sinusitis Drugs NSAIDS , by Region USD Million (2022-2027)
  • Table 150. Sinusitis Drugs Decongestant and Mucolytic , by Region USD Million (2022-2027)
  • Table 151. Sinusitis Drugs Nasal Irrigation , by Region USD Million (2022-2027)
  • Table 152. Sinusitis Drugs: by End User(USD Million)
  • Table 153. Sinusitis Drugs Adults , by Region USD Million (2022-2027)
  • Table 154. Sinusitis Drugs Teenagers , by Region USD Million (2022-2027)
  • Table 155. Sinusitis Drugs Children , by Region USD Million (2022-2027)
  • Table 156. South America Sinusitis Drugs, by Country USD Million (2022-2027)
  • Table 157. South America Sinusitis Drugs, by Type USD Million (2022-2027)
  • Table 158. South America Sinusitis Drugs, by Application USD Million (2022-2027)
  • Table 159. South America Sinusitis Drugs, by Treatment USD Million (2022-2027)
  • Table 160. South America Sinusitis Drugs, by End User USD Million (2022-2027)
  • Table 161. Brazil Sinusitis Drugs, by Type USD Million (2022-2027)
  • Table 162. Brazil Sinusitis Drugs, by Application USD Million (2022-2027)
  • Table 163. Brazil Sinusitis Drugs, by Treatment USD Million (2022-2027)
  • Table 164. Brazil Sinusitis Drugs, by End User USD Million (2022-2027)
  • Table 165. Argentina Sinusitis Drugs, by Type USD Million (2022-2027)
  • Table 166. Argentina Sinusitis Drugs, by Application USD Million (2022-2027)
  • Table 167. Argentina Sinusitis Drugs, by Treatment USD Million (2022-2027)
  • Table 168. Argentina Sinusitis Drugs, by End User USD Million (2022-2027)
  • Table 169. Rest of South America Sinusitis Drugs, by Type USD Million (2022-2027)
  • Table 170. Rest of South America Sinusitis Drugs, by Application USD Million (2022-2027)
  • Table 171. Rest of South America Sinusitis Drugs, by Treatment USD Million (2022-2027)
  • Table 172. Rest of South America Sinusitis Drugs, by End User USD Million (2022-2027)
  • Table 173. Asia Pacific Sinusitis Drugs, by Country USD Million (2022-2027)
  • Table 174. Asia Pacific Sinusitis Drugs, by Type USD Million (2022-2027)
  • Table 175. Asia Pacific Sinusitis Drugs, by Application USD Million (2022-2027)
  • Table 176. Asia Pacific Sinusitis Drugs, by Treatment USD Million (2022-2027)
  • Table 177. Asia Pacific Sinusitis Drugs, by End User USD Million (2022-2027)
  • Table 178. China Sinusitis Drugs, by Type USD Million (2022-2027)
  • Table 179. China Sinusitis Drugs, by Application USD Million (2022-2027)
  • Table 180. China Sinusitis Drugs, by Treatment USD Million (2022-2027)
  • Table 181. China Sinusitis Drugs, by End User USD Million (2022-2027)
  • Table 182. Japan Sinusitis Drugs, by Type USD Million (2022-2027)
  • Table 183. Japan Sinusitis Drugs, by Application USD Million (2022-2027)
  • Table 184. Japan Sinusitis Drugs, by Treatment USD Million (2022-2027)
  • Table 185. Japan Sinusitis Drugs, by End User USD Million (2022-2027)
  • Table 186. India Sinusitis Drugs, by Type USD Million (2022-2027)
  • Table 187. India Sinusitis Drugs, by Application USD Million (2022-2027)
  • Table 188. India Sinusitis Drugs, by Treatment USD Million (2022-2027)
  • Table 189. India Sinusitis Drugs, by End User USD Million (2022-2027)
  • Table 190. South Korea Sinusitis Drugs, by Type USD Million (2022-2027)
  • Table 191. South Korea Sinusitis Drugs, by Application USD Million (2022-2027)
  • Table 192. South Korea Sinusitis Drugs, by Treatment USD Million (2022-2027)
  • Table 193. South Korea Sinusitis Drugs, by End User USD Million (2022-2027)
  • Table 194. Taiwan Sinusitis Drugs, by Type USD Million (2022-2027)
  • Table 195. Taiwan Sinusitis Drugs, by Application USD Million (2022-2027)
  • Table 196. Taiwan Sinusitis Drugs, by Treatment USD Million (2022-2027)
  • Table 197. Taiwan Sinusitis Drugs, by End User USD Million (2022-2027)
  • Table 198. Australia Sinusitis Drugs, by Type USD Million (2022-2027)
  • Table 199. Australia Sinusitis Drugs, by Application USD Million (2022-2027)
  • Table 200. Australia Sinusitis Drugs, by Treatment USD Million (2022-2027)
  • Table 201. Australia Sinusitis Drugs, by End User USD Million (2022-2027)
  • Table 202. Rest of Asia-Pacific Sinusitis Drugs, by Type USD Million (2022-2027)
  • Table 203. Rest of Asia-Pacific Sinusitis Drugs, by Application USD Million (2022-2027)
  • Table 204. Rest of Asia-Pacific Sinusitis Drugs, by Treatment USD Million (2022-2027)
  • Table 205. Rest of Asia-Pacific Sinusitis Drugs, by End User USD Million (2022-2027)
  • Table 206. Europe Sinusitis Drugs, by Country USD Million (2022-2027)
  • Table 207. Europe Sinusitis Drugs, by Type USD Million (2022-2027)
  • Table 208. Europe Sinusitis Drugs, by Application USD Million (2022-2027)
  • Table 209. Europe Sinusitis Drugs, by Treatment USD Million (2022-2027)
  • Table 210. Europe Sinusitis Drugs, by End User USD Million (2022-2027)
  • Table 211. Germany Sinusitis Drugs, by Type USD Million (2022-2027)
  • Table 212. Germany Sinusitis Drugs, by Application USD Million (2022-2027)
  • Table 213. Germany Sinusitis Drugs, by Treatment USD Million (2022-2027)
  • Table 214. Germany Sinusitis Drugs, by End User USD Million (2022-2027)
  • Table 215. France Sinusitis Drugs, by Type USD Million (2022-2027)
  • Table 216. France Sinusitis Drugs, by Application USD Million (2022-2027)
  • Table 217. France Sinusitis Drugs, by Treatment USD Million (2022-2027)
  • Table 218. France Sinusitis Drugs, by End User USD Million (2022-2027)
  • Table 219. Italy Sinusitis Drugs, by Type USD Million (2022-2027)
  • Table 220. Italy Sinusitis Drugs, by Application USD Million (2022-2027)
  • Table 221. Italy Sinusitis Drugs, by Treatment USD Million (2022-2027)
  • Table 222. Italy Sinusitis Drugs, by End User USD Million (2022-2027)
  • Table 223. United Kingdom Sinusitis Drugs, by Type USD Million (2022-2027)
  • Table 224. United Kingdom Sinusitis Drugs, by Application USD Million (2022-2027)
  • Table 225. United Kingdom Sinusitis Drugs, by Treatment USD Million (2022-2027)
  • Table 226. United Kingdom Sinusitis Drugs, by End User USD Million (2022-2027)
  • Table 227. Netherlands Sinusitis Drugs, by Type USD Million (2022-2027)
  • Table 228. Netherlands Sinusitis Drugs, by Application USD Million (2022-2027)
  • Table 229. Netherlands Sinusitis Drugs, by Treatment USD Million (2022-2027)
  • Table 230. Netherlands Sinusitis Drugs, by End User USD Million (2022-2027)
  • Table 231. Rest of Europe Sinusitis Drugs, by Type USD Million (2022-2027)
  • Table 232. Rest of Europe Sinusitis Drugs, by Application USD Million (2022-2027)
  • Table 233. Rest of Europe Sinusitis Drugs, by Treatment USD Million (2022-2027)
  • Table 234. Rest of Europe Sinusitis Drugs, by End User USD Million (2022-2027)
  • Table 235. MEA Sinusitis Drugs, by Country USD Million (2022-2027)
  • Table 236. MEA Sinusitis Drugs, by Type USD Million (2022-2027)
  • Table 237. MEA Sinusitis Drugs, by Application USD Million (2022-2027)
  • Table 238. MEA Sinusitis Drugs, by Treatment USD Million (2022-2027)
  • Table 239. MEA Sinusitis Drugs, by End User USD Million (2022-2027)
  • Table 240. Middle East Sinusitis Drugs, by Type USD Million (2022-2027)
  • Table 241. Middle East Sinusitis Drugs, by Application USD Million (2022-2027)
  • Table 242. Middle East Sinusitis Drugs, by Treatment USD Million (2022-2027)
  • Table 243. Middle East Sinusitis Drugs, by End User USD Million (2022-2027)
  • Table 244. Africa Sinusitis Drugs, by Type USD Million (2022-2027)
  • Table 245. Africa Sinusitis Drugs, by Application USD Million (2022-2027)
  • Table 246. Africa Sinusitis Drugs, by Treatment USD Million (2022-2027)
  • Table 247. Africa Sinusitis Drugs, by End User USD Million (2022-2027)
  • Table 248. North America Sinusitis Drugs, by Country USD Million (2022-2027)
  • Table 249. North America Sinusitis Drugs, by Type USD Million (2022-2027)
  • Table 250. North America Sinusitis Drugs, by Application USD Million (2022-2027)
  • Table 251. North America Sinusitis Drugs, by Treatment USD Million (2022-2027)
  • Table 252. North America Sinusitis Drugs, by End User USD Million (2022-2027)
  • Table 253. United States Sinusitis Drugs, by Type USD Million (2022-2027)
  • Table 254. United States Sinusitis Drugs, by Application USD Million (2022-2027)
  • Table 255. United States Sinusitis Drugs, by Treatment USD Million (2022-2027)
  • Table 256. United States Sinusitis Drugs, by End User USD Million (2022-2027)
  • Table 257. Canada Sinusitis Drugs, by Type USD Million (2022-2027)
  • Table 258. Canada Sinusitis Drugs, by Application USD Million (2022-2027)
  • Table 259. Canada Sinusitis Drugs, by Treatment USD Million (2022-2027)
  • Table 260. Canada Sinusitis Drugs, by End User USD Million (2022-2027)
  • Table 261. Mexico Sinusitis Drugs, by Type USD Million (2022-2027)
  • Table 262. Mexico Sinusitis Drugs, by Application USD Million (2022-2027)
  • Table 263. Mexico Sinusitis Drugs, by Treatment USD Million (2022-2027)
  • Table 264. Mexico Sinusitis Drugs, by End User USD Million (2022-2027)
  • Table 265. Research Programs/Design for This Report
  • Table 266. Key Data Information from Secondary Sources
  • Table 267. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Sinusitis Drugs: by Type USD Million (2016-2021)
  • Figure 5. Global Sinusitis Drugs: by Application USD Million (2016-2021)
  • Figure 6. Global Sinusitis Drugs: by Treatment USD Million (2016-2021)
  • Figure 7. Global Sinusitis Drugs: by End User USD Million (2016-2021)
  • Figure 8. South America Sinusitis Drugs Share (%), by Country
  • Figure 9. Asia Pacific Sinusitis Drugs Share (%), by Country
  • Figure 10. Europe Sinusitis Drugs Share (%), by Country
  • Figure 11. MEA Sinusitis Drugs Share (%), by Country
  • Figure 12. North America Sinusitis Drugs Share (%), by Country
  • Figure 13. Global Sinusitis Drugs share by Players 2021 (%)
  • Figure 14. Global Sinusitis Drugs share by Players (Top 3) 2021(%)
  • Figure 15. Global Sinusitis Drugs share by Players (Top 5) 2021(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Sanofi S.A. (France) Revenue, Net Income and Gross profit
  • Figure 18. Sanofi S.A. (France) Revenue: by Geography 2021
  • Figure 19. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 20. Pfizer Inc. (United States) Revenue: by Geography 2021
  • Figure 21. Novartis International AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 22. Novartis International AG (Switzerland) Revenue: by Geography 2021
  • Figure 23. Johnson & Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 24. Johnson & Johnson (United States) Revenue: by Geography 2021
  • Figure 25. Merck & Co., Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 26. Merck & Co., Inc. (United States) Revenue: by Geography 2021
  • Figure 27. AstraZeneca plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 28. AstraZeneca plc (United Kingdom) Revenue: by Geography 2021
  • Figure 29. Amgen Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 30. Amgen Inc. (United States) Revenue: by Geography 2021
  • Figure 31. Teva Pharmaceutical Industries Ltd. (Israel) Revenue, Net Income and Gross profit
  • Figure 32. Teva Pharmaceutical Industries Ltd. (Israel) Revenue: by Geography 2021
  • Figure 33. Global Sinusitis Drugs: by Type USD Million (2022-2027)
  • Figure 34. Global Sinusitis Drugs: by Application USD Million (2022-2027)
  • Figure 35. Global Sinusitis Drugs: by Treatment USD Million (2022-2027)
  • Figure 36. Global Sinusitis Drugs: by End User USD Million (2022-2027)
  • Figure 37. South America Sinusitis Drugs Share (%), by Country
  • Figure 38. Asia Pacific Sinusitis Drugs Share (%), by Country
  • Figure 39. Europe Sinusitis Drugs Share (%), by Country
  • Figure 40. MEA Sinusitis Drugs Share (%), by Country
  • Figure 41. North America Sinusitis Drugs Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Sanofi S.A. (France)
  • Pfizer Inc. (United States)
  • Novartis International AG (Switzerland)
  • Johnson & Johnson (United States)
  • Merck & Co., Inc. (United States)
  • AstraZeneca plc (United Kingdom)
  • Amgen Inc. (United States)
  • Teva Pharmaceutical Industries Ltd. (Israel)
Select User Access Type

Key Highlights of Report


Jan 2021 207 Pages 61 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Sinusitis Drugs Market Quantitative research analysis
Global Sinusitis Drugs Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The prominent players of Global Sinusitis Drugs market are Sanofi S.A. (France), Pfizer Inc. (United States), Novartis International AG (Switzerland), Johnson & Johnson (United States), Merck & Co., Inc. (United States), AstraZeneca plc (United Kingdom), Amgen Inc. (United States) and Teva Pharmaceutical Industries Ltd. (Israel).
In this highly competitive & fast evolving Sinusitis Drugs industry, the top strategic priorities would remain consistent like innovation, R&D, and M&A.
Acute Sinusitis and Chronic Sinusitis are the potential customers of Sinusitis Drugs industry.

Know More About Global Sinusitis Drugs Market Report?

Have a Query? Click Here

Other Related Reports

Barbiturate Drugs Comprehensive Study by Type (Phenobarbital, Amobarbital, Secobarbital, Pentobarbital, Others), Application (Insomnia, Seizures, Headaches, Others), Nature (Ultra-Short Acting Barbit...
$ 3750
Pigmented Villonodular Synovitis Drug Comprehensive Study by Type (Cabiralizumab, Emactuzumab, Mcs-110, Nilotinib, Others), Application (Reduces Swelling, Relieves Pain, Others), Distribution Channel...
$ 3650
Immunotherapy Drugs Comprehensive Study by Type (Monoclonal Antibodies, Adult Vaccines (Preventive Vaccines, Therapeutic Vaccines), Checkpoint Inhibitors, Interferons Alpha & Beta, Interleukins, Othe...
$ 3750
Allyl Methacrylate Comprehensive Study by Type (Allyl Methacrylate 98%, Allyl Methacrylate 99.5%), Application (Paints& Coatings, Floor Polishes, Dentistry Materials, Other), Distribution Channel (Di...
$ 3350
Cat Allergy Comprehensive Study by Type (Antihistamine, Decongestants Medication), Application (Hospital, Ambulatory Surgical Centers), Test Type (Scratch test, Intradermal test) Players and Region -...
$ 3500
Protease Inhibitors Comprehensive Study by Application (Commodity Protease Inhibitor, Research Tool Protease Inhibitor, Protease Inhibitor Drugs), Mechanism of Action (Serine Protease Inhibitors, Cys...
$ 3750